Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer
Authors
Keywords
Rapamycin, Oxaliplatin, mTOR Inhibitor, mTOR Signaling, SW480 Cell Line
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 21, Issue 1, Pages 179-188
Publisher
Springer Nature
Online
2013-08-02
DOI
10.1245/s10434-013-3146-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer
- (2012) Chloe E. Atreya et al. INVESTIGATIONAL NEW DRUGS
- High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
- (2012) Xian-Rui Wu et al. JOURNAL OF SURGICAL ONCOLOGY
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
- (2011) P. Gulhati et al. CANCER RESEARCH
- Colon cancer stem cells: implications in carcinogenesis
- (2010) Matthew et al. Frontiers in Bioscience-Landmark
- Colon Cancer Stem Cells: Promise of Targeted Therapy
- (2010) Matilde Todaro et al. GASTROENTEROLOGY
- Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
- (2010) Didier Roulin et al. Molecular Cancer
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis
- (2009) E. H. Huang et al. CANCER RESEARCH
- Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
- (2009) P. Gulhati et al. CLINICAL CANCER RESEARCH
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
- (2008) Jing Yang et al. DEVELOPMENTAL CELL
- ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells
- (2008) Julie Douville et al. STEM CELLS AND DEVELOPMENT
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More